



Trends in triptan, CGRP monoclonal antibody and gepant prescription rates in a large healthcare system in Boston, MA, USA from 2018-2024

Patrick Ebbert, MD¹, Pamela Rist, ScD^{2,3}, Elizabeth Loder, MD, MPH¹, Angeliki Vgontzas, MD¹

¹Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA ² Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, ³Department of Epidemiology, Harvard T.H.Chan School of Public Health, Boston, MA, USA

OBJECTIVE


- To describe triptan and CGRP inhibitor prescription rates by patient demographics in the Mass General Brigham Health System from 2018-2024

METHODS

- Electronic health record data from the Mass General Brigham Research Data Registry (RPDR)
- Patients ≥ 18 years with a migraine diagnosis (ICD-10 G43) and prescribed a triptan or CGRP inhibitor May 1, 2018 - November 1, 2024
- We describe annual prescription data by patient demographics
- Categorical data compared using chi square with Yates correction. A p-value less than 0.01 was considered statistically significant.

RESULTS

Annual prescription rates of triptans, CGRP monoclonal antibodies and gepants by demographic characteristics



Co-prescriptions of triptan and CGRP-inhibitors

		Only Triptan N = 35,558	Only CGRP* N = 4740	Tried CGRP and Triptans Separately* N = 5265	CGRP + Triptan at same time* N = 3635
Age, n (%)	Under 40	13066 (36.7)	1420 (30.0)	1458 (27.7)	1239 (34.1)
	40-59	14373 (40.4)	1930 (40.7)	2348 (44.6)	1688 (46.4)
	60+	7734 (21.8)	1351 (28.5)	1124 (21.3)	683 (18.8)
Sex, n (%)	Female	30135 (84.7)	4029 (85.0)	4676 (88.8)	3235 (89.0)
	Male	5418 (15.2)	709 (15.0)	596 (11.3)	395 (10.9)
	White	27673 (77.8)	4126 (87.0)	4527 (86.0)	3160 (86.9)
Race/ Ethnicity, n (%)	Black	2265 (2.8)	136 (2.1)	187 (2.2)	121 (2.1)
	Asian	989 (2.8)	99 (2.1)	115 (2.2)	77 (2.1)
	Other	4631 (13.0)	379 (8.0)	438 (8.3)	275 (7.6)
Migraine diagnosis, n (%)	Hispanic	1783 (5.0)	63 (1.3)	130 (2.5)	85 (2.3)
	Chronic M	6530 (18.4)	2091 (44.1)	2874 (54.6)	2324 (63.9)
	Aura	10531 (29.6)	1589 (33.5)	2059 (39.1)	1305 (35.9)

*Age, Sex, Race/Ethnicity and migraine diagnoses differed when compared to the "only triptan" group ($p < 0.001$) except when comparing sex between the only CGRP group and only triptan group ($p = 0.63$)

- 147,153 patients with migraine, 41.2% prescribed a triptan, CGRP mAb or gepant
- Prescription rates higher in 2024 than in 2018 for triptans (30.3% vs 22.5%), CGRP mAbs (7.1% vs 2.0%) and gepants (10.2% vs 1.9%) [year 2020], $p < 0.001$ for all

CONCLUSIONS

- Overall, there was an increase in the prescription rates for triptans, gepants and CGRP mABs in each demographic group from 2018-2024, although disparities were noted.